European Biotech Acquisition Corp. (EBAC)
| Market Cap | 144.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 14.90M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 16 |
| Last Price | $9.70 |
| Previous Close | $9.70 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 9.70 - 9.72 |
| Day's Volume | - |
| 52-Week Range | 9.69 - 10.48 |
NEW YORK--(BUSINESS WIRE)--European Biotech Acquisition Corp. receives expected notification from Nasdaq related to delayed quarterly report.
European Biotech Acquisition Corp. (the “Company”) announced today that it priced its initial public offering of 12,000,000 units at $10.00 per unit.
The last year’s SPAC boom has been dominated so far by US-based VCs. Now a prominent European biotech executive and a couple investors are getting in on the game.
European Biotech Acquisition, a blank check company formed by LSP targeting the life sciences industry in Europe, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
European Biotech Acquisition Corp. has filed to go public with an IPO on the NASDAQ.
About EBAC
European Biotech Acquisition Corp. (“EBAC”) is a newly organized blank check company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. We intend to capitalize on the ability of our management team to identify promising opportunities in the life sciences industry in Europe. LSP, an affiliate of our sponsor, is one of Europe’s largest and most experienced healthcare investment firms. With a committed t... [Read more...]
| Industry Shell Companies | IPO Date Mar 16, 2021 |
| CEO Eduardo Bravo Fernandez de Araoz | Country Netherlands |
| Stock Exchange NASDAQ | Ticker Symbol EBAC |